NAS:XENE (Canada) Also trade in: Germany

Xenon Pharmaceuticals Inc

$ 9.75 0 (0%)
Volume: 57,852 Avg Vol (1m): 100,649
Market Cap $: 251.29 Mil Enterprise Value $: 163.74 Mil
P/E (TTM): 0.00 P/B: 2.99
Earnings Power Value -282.78
Net Current Asset Value 3.19
Tangible Book 3.28
Projected FCF -4.1
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 7.29
Cash-To-Debt ranked lower than
60.95% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
XENE: 7.29
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 5.1, Med: 10000, Max: 10000
Current: 7.29
5.1
10000
Debt-to-Equity 0.16
Debt-to-Equity ranked higher than
54.60% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
XENE: 0.16
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -0.02, Med: 0.16, Max: 0.24
Current: 0.16
-0.02
0.24
Debt-to-EBITDA -0.38
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
XENE: -0.38
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -0.49, Med: -0.46, Max: -0.23
Current: -0.38
-0.49
-0.23
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.89
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC 0%
WACC 13.8%

Profitability & Growth : 2/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
ROE % -49.70
ROE ranked lower than
60.06% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
XENE: -49.7
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -61.51, Med: -41.12, Max: -23.54
Current: -49.7
-61.51
-23.54
ROA % -44.71
ROA ranked lower than
66.42% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
XENE: -44.71
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -54.05, Med: -20.81, Max: 20.43
Current: -44.71
-54.05
20.43
ROC (Joel Greenblatt) % -3789.15
ROC (Joel Greenblatt) ranked lower than
70.66% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
XENE: -3789.15
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -3789.15, Med: -419.31, Max: 539.88
Current: -3789.15
-3789.15
539.88
3-Year Total Revenue Growth Rate -100.00
3-Year Revenue Growth Rate ranked lower than
89.40% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
XENE: -100
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -100, Med: -79.2, Max: 29.7
Current: -100
-100
29.7
3-Year Total EBITDA Growth Rate -57.50
3-Year EBITDA Growth Rate ranked lower than
100.00% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
XENE: -42.1
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
N/A
3-Year EPS w/o NRI Growth Rate -14.00
3-Year EPS w/o NRI Growth Rate ranked lower than
100.00% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
XENE: -14
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: -14
Current: -14
0
-14

» XENE's 30-Y Financials

Financials (Next Earnings Date: 2019-08-07)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:XENE

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 3741
Compare NAS:PTGX NAS:TOCA XTAE:KMDA NAS:XFOR XTER:MDG1 NAS:CNCE NAS:UROV NAS:ATHX XBRU:CYAD NAS:CERC NAS:NVAX NAS:MRSN NAS:CALA NAS:MRKR SHSE:603139 TPE:1760 AMEX:OCX NAS:STRO AMEX:XXII NAS:PETX
Traded in other countries XP0.Germany
Address 200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8
Xenon Pharmaceuticals Inc is a Canadian clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of therapeutics for orphan indications. The company has developed a gene therapy referred as Glybera for the treatment of a subset of patients with the orphan lipid disorder lipoprotein lipase deficiency. The other product candidates include TV-45070, GDC-0310, XEN801 and XEN901 and other compounds in preclinical and discovery pipeline.

Ratios

Current vs industry vs history
PB Ratio 2.99
PB Ratio ranked lower than
70.37% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
XENE: 2.99
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.96, Med: 2.12, Max: 13.06
Current: 2.99
0.96
13.06
EV-to-EBIT -4.07
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
XENE: -4.07
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -11.4, Med: -2.5, Max: 50.2
Current: -4.07
-11.4
50.2
EV-to-EBITDA -4.09
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
XENE: -4.09
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -13.3, Med: -2.7, Max: 42
Current: -4.09
-13.3
42
Current Ratio 17.57
Current Ratio ranked higher than
91.81% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
XENE: 17.57
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 2.62, Med: 14.33, Max: 29.48
Current: 17.57
2.62
29.48
Quick Ratio 17.57
Quick Ratio ranked higher than
91.81% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
XENE: 17.57
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 2.62, Med: 14.33, Max: 29.48
Current: 17.57
2.62
29.48

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -20.60
3-Year Share Buyback Rate ranked higher than
65.46% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
XENE: -20.6
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -104.1, Med: -88.8, Max: -8.3
Current: -20.6
-104.1
-8.3

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 2.97
Price-to-Tangible-Book ranked lower than
62.75% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
XENE: 2.97
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.12, Med: 2, Max: 10.4
Current: 2.97
1.12
10.4
Earnings Yield (Joel Greenblatt) % -24.71
Earnings Yield (Greenblatt) ranked lower than
63.37% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
XENE: -24.71
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -8117.4, Med: -29.4, Max: 5221.5
Current: -24.71
-8117.4
5221.5

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N